Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 19, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions

Intrahepatic Cholangiocarcinoma

Interventions

DRUG

Adebrelimab

1200mg，i.v. , q3w

DRUG

Lenvatinib

8mg,qd

DRUG

Gemcitabine

800 mg/m2，q3w

DRUG

Oxaliplatin

85 mg/m2，q3w

Trial Locations (3)

RECRUITING

Ningbo Medical Center Lihuili Hospital, Ningbo

RECRUITING

West China Hospital, Chengdu

RECRUITING

The First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors

collaborator

Jiangsu Hengrui Pharmaceutical Co., Ltd.

INDUSTRY

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER